UNSPSC 51182306: Tesamorelin acetate

This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C221H366N72O67S.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGW5H38VE3. The term tesamorelin acetate is a United States Adopted Name designation. As of Q4 2014, TESAMORELIN ACETATE remains the US FDA Preferred Term for this commodity. Tesamorelin acetate bears US NLM identifiers UMLS ID C2955463 and NCI Concept Code C90852.

UNSPSC 51182306 Tesamorelin acetate is a Commodity code encompassing growth hormone-releasing hormone analog pharmaceuticals supplied through state and local procurement channels, though recent activity shows the code operating within broader generic multi-source pharmaceutical and OTC product frameworks rather than in single-product solicitations. State and local governments procure tesamorelin and related pharmaceutical products through cooperative purchasing alliances and state health and human services agencies that source branded and generic medications for Medicaid programs, correctional facilities, public health clinics, and other state-administered care settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body visible in recent activity under this code family, operating a multi-state purchasing vehicle that includes participating agencies in Minnesota and Oregon.

MMCAP issued a Request for Proposal (RFP) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response date of March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with awarded agreements effective July 1, 2026. The RFP emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintenance of relationships with at least two of three authorized wholesalers, and flexible pricing structures including flat price, net price formats, or WAC-minus models. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, with contract terms of two years for new responders and optional extensions at MMCAP's discretion. The solicitation does not disclose specific award values or budget ranges, though vendors should anticipate a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation.